Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Versus Clonidine in TAP Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II physical status patients.~* Age between 3 and 8 years.~* Children undergoing laparoscopic orcheopexy.~Exclusion Criteria:~* Parent refusal~* History of developmental delay or mental retardation, which will make observational pain intensity assessment difficult~* Hypersensitivity to any local anesthetics~* Bleeding diathesis~* History of renal, hepatic, cardiac, upper or lower airway or neurological diseases~* Any sign of infection at the puncture site of the proposed block~* History of sleep apnea with which postoperative ventilation may be required

- Gender: MALE
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- DEXMEDETOMIDINE (Type: ACTIVE_COMPARATOR): patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
- CLONIDINE (Type: ACTIVE_COMPARATOR): patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
- LEVOBUPIVACAINE (Type: ACTIVE_COMPARATOR): patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).

Based on this trial design, predict the completion outcome and termination type (if applicable).